MEIP240920C3000
- 0.58
- 0.000.00%
MEI Pharma Newsroom
MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives
MEI Pharma Explores Strategic Shifts, Leadership Changes
Express News | MEI Pharma Inc: Continuing to Conduct Certain Non-Clinical Activities Related to Co's Drug Candidate Assets
Express News | MEI Pharma Inc: Intended to Promptly Discontinue Clinical Development of Voruciclib
Express News | MEI Pharma Inc: Board Determined to Begin Evaluation of Strategic Alternatives
MEI Pharma Explores Strategic Options, Halts Drug Development
Laidlaw Cuts MEI Pharma to Hold Over Shutdown Concerns
MEI Pharma Cut to Hold From Buy by Laidlaw & Co.
Laidlaw & Co. Downgrades MEI Pharma to Hold
MEI Pharma Analyst Ratings
Laidlaw Initiates MEI Pharma(MEIP.US) With Hold Rating
Laidlaw analyst Yale Jen initiates coverage on $MEI Pharma(MEIP.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 29.4% and a total average return of -6.5% over
MEI Pharma Announces Executive Changes and Strategic Overhaul
Sector Update: Health Care Stocks Rise Late Afternoon
Why CrowdStrike Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Brookline Capital Downgrades MEI Pharma(MEIP.US) to Hold Rating
Brookline Capital analyst Leah R. Cann downgrades $MEI Pharma(MEIP.US)$ to a hold rating.According to TipRanks data, the analyst has a success rate of 37.5% and a total average return of -3.0% over
Express News | MEI Pharma Shares up 16.8% Premarket on Workforce Reduction Plan
MEI Pharma Shares Are Trading Higher After the Company Announced It Is Considering Strategic Alternatives.
Express News | MEI Pharma Inc - Appoints Frederick W. Driscoll as Chairperson
Express News | MEI Pharma Inc - Appoints Justin File as Acting CEO
Express News | MEI Pharma Inc - Appointed Justin "Jay" File, to Assume Position of Acting Chief Executive Officer Upon Urso's Departure